Last reviewed · How we verify
Sanofi Pasteur Menactra® vaccine — Competitive Intelligence Brief
marketed
Conjugate vaccine
Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y)
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Sanofi Pasteur Menactra® vaccine (Sanofi Pasteur Menactra® vaccine) — Walvax Biotechnology Co., Ltd.. Menactra is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by presenting polysaccharide antigens linked to a carrier protein.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sanofi Pasteur Menactra® vaccine TARGET | Sanofi Pasteur Menactra® vaccine | Walvax Biotechnology Co., Ltd. | marketed | Conjugate vaccine | Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y) | |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| NeisVac-C® | NeisVac-C® | Merck Sharp & Dohme LLC | marketed | Meningococcal conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| MenACWY-CRM (Menveo) | MenACWY-CRM (Menveo) | GlaxoSmithKline | marketed | Conjugate vaccine | ||
| Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | Sanofi Pasteur, a Sanofi Company | marketed | Conjugate vaccine | Neisseria meningitidis polysaccharide capsule | |
| PedvaxHIB® | PedvaxHIB® | GlaxoSmithKline | marketed | Conjugate vaccine | Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide | |
| pneumococcal conjugate 13 valent vaccine | pneumococcal conjugate 13 valent vaccine | University of Siena | marketed | Conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (13 serotypes) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Conjugate vaccine class)
- GlaxoSmithKline · 26 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
- CanSino Biologics Inc. · 3 drugs in this class
- MCM Vaccines B.V. · 3 drugs in this class
- Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
- Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
- PT Bio Farma · 2 drugs in this class
- LG Life Sciences · 2 drugs in this class
- Walvax Biotechnology Co., Ltd. · 2 drugs in this class
- Heinrich-Heine University, Duesseldorf · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sanofi Pasteur Menactra® vaccine CI watch — RSS
- Sanofi Pasteur Menactra® vaccine CI watch — Atom
- Sanofi Pasteur Menactra® vaccine CI watch — JSON
- Sanofi Pasteur Menactra® vaccine alone — RSS
- Whole Conjugate vaccine class — RSS
Cite this brief
Drug Landscape (2026). Sanofi Pasteur Menactra® vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/sanofi-pasteur-menactra-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab